JP2022533009A5 - - Google Patents
Info
- Publication number
- JP2022533009A5 JP2022533009A5 JP2021564299A JP2021564299A JP2022533009A5 JP 2022533009 A5 JP2022533009 A5 JP 2022533009A5 JP 2021564299 A JP2021564299 A JP 2021564299A JP 2021564299 A JP2021564299 A JP 2021564299A JP 2022533009 A5 JP2022533009 A5 JP 2022533009A5
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- seq
- immune complex
- amino acid
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024193438A JP2025023995A (ja) | 2019-04-29 | 2024-11-05 | 抗ｃｄ１２３免疫複合体を含む治療的組み合わせ |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962839974P | 2019-04-29 | 2019-04-29 | |
| US62/839,974 | 2019-04-29 | ||
| US201962860598P | 2019-06-12 | 2019-06-12 | |
| US62/860,598 | 2019-06-12 | ||
| PCT/US2020/030478 WO2020223351A1 (en) | 2019-04-29 | 2020-04-29 | Therapeutic combinations comprising anti-cd123 immunoconjugates |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024193438A Division JP2025023995A (ja) | 2019-04-29 | 2024-11-05 | 抗ｃｄ１２３免疫複合体を含む治療的組み合わせ |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022533009A JP2022533009A (ja) | 2022-07-21 |
| JP2022533009A5 true JP2022533009A5 (enExample) | 2023-04-13 |
| JP7585231B2 JP7585231B2 (ja) | 2024-11-18 |
Family
ID=73029177
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021564299A Active JP7585231B2 (ja) | 2019-04-29 | 2020-04-29 | 抗ｃｄ１２３免疫複合体を含む治療的組み合わせ |
| JP2024193438A Pending JP2025023995A (ja) | 2019-04-29 | 2024-11-05 | 抗ｃｄ１２３免疫複合体を含む治療的組み合わせ |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024193438A Pending JP2025023995A (ja) | 2019-04-29 | 2024-11-05 | 抗ｃｄ１２３免疫複合体を含む治療的組み合わせ |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11701428B2 (enExample) |
| EP (1) | EP3962528A4 (enExample) |
| JP (2) | JP7585231B2 (enExample) |
| KR (1) | KR20220004669A (enExample) |
| CN (1) | CN113853217A (enExample) |
| AU (1) | AU2020265225A1 (enExample) |
| CA (1) | CA3137454A1 (enExample) |
| IL (1) | IL287446A (enExample) |
| MA (1) | MA55816A (enExample) |
| SG (1) | SG11202110702WA (enExample) |
| TW (1) | TWI865521B (enExample) |
| WO (1) | WO2020223351A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20220004669A (ko) | 2019-04-29 | 2022-01-11 | 이뮤노젠 아이엔씨 | 항-cd123 면역접합체를 포함하는 치료적 조합물 |
| IL308321A (en) * | 2021-05-11 | 2024-01-01 | Abbvie Inc | Venetoclax dosing regimens for use in treating myelodysplastic syndromes in combination with azacitidine |
| WO2024123765A1 (en) * | 2022-12-08 | 2024-06-13 | Immunogen, Inc. | Therapeutic combinations comprising anti-cd123 antibody-drug conjugates and anti-cd47 antibodies |
| US20260083749A1 (en) * | 2024-05-10 | 2026-03-26 | Immunogen, Inc. | Anti-cd123 immunoconjugates for the treatment of acute myeloid leukemia |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8163279B2 (en) | 2007-04-13 | 2012-04-24 | Stemline Therapeutics, Inc. | IL3Rα antibody conjugates and uses thereof |
| WO2009080831A1 (en) * | 2007-12-26 | 2009-07-02 | Biotest Ag | Method of decreasing cytotoxic side-effects and improving efficacy of immunoconjugates |
| WO2012142411A1 (en) * | 2011-04-15 | 2012-10-18 | Clavis Pharma Asa | Systems and methods for detecting hent1 expression in hematological disorders |
| TW201709932A (zh) | 2015-06-12 | 2017-03-16 | 西雅圖遺傳學公司 | Ｃｄ１２３抗體及其共軛物 |
| SMT202000614T1 (it) | 2015-06-29 | 2021-01-05 | Immunogen Inc | Coniugati di anticorpi ingegnerizzati con cisteina |
| AU2016285552B2 (en) | 2015-06-29 | 2022-10-13 | Immunogen, Inc. | Anti-CD123 antibodies and conjugates and derivatives thereof |
| US10695352B2 (en) * | 2015-10-15 | 2020-06-30 | Celgene Corporation | Combination therapy for treating malignancies |
| KR102124715B1 (ko) * | 2015-11-03 | 2020-06-18 | 제넨테크, 인크. | 암의 치료를 위한 bcl-2 억제제 및 mek 억제제의 조합물 |
| US20170189548A1 (en) | 2015-11-25 | 2017-07-06 | Immunogen, Inc. | Pharmaceutical formulations and methods of use thereof |
| WO2017160954A1 (en) | 2016-03-15 | 2017-09-21 | Seattle Genetics, Inc. | Combinations of pbd-based antibody drug conjugates with bcl-2 inhibitors |
| EP3318276A1 (en) * | 2016-11-04 | 2018-05-09 | Janssen Biotech, Inc. | Combinations of a telomerase inhibitor and a bcl-2 inhibitor for the treatment of hematological cancers |
| WO2018098258A2 (en) | 2016-11-23 | 2018-05-31 | Immunogen, Inc. | Selective sulfonation of benzodiazepine derivatives |
| KR20200041834A (ko) * | 2017-06-01 | 2020-04-22 | 젠코어 인코포레이티드 | Cd123 및 cd3에 결합하는 이중특이성 항체 |
| GB2567613A (en) * | 2017-06-16 | 2019-04-24 | Argenx Bvba | Treatment for acute myeloid leukaemia |
| US20190062428A1 (en) * | 2017-06-19 | 2019-02-28 | Surface Oncology, Inc. | Combination of anti-cd47 antibodies and cell death-inducing agents, and uses thereof |
| CA3069558A1 (en) | 2017-07-09 | 2019-01-17 | Biosight Ltd. | Combination cancer therapy |
| JP2020528061A (ja) * | 2017-07-26 | 2020-09-17 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | ＢＥＴ阻害剤、Ｂｃｌ−２阻害剤及び抗ＣＤ２０抗体を用いた併用療法 |
| EP3684409A4 (en) * | 2017-09-22 | 2021-06-23 | Immunogen, Inc. | SEPARATION OF TRIPLE LIGHT CHAIN ANTIBODIES USING CATION EXCHANGE CHROMATOGRAPHY |
| KR20200070254A (ko) * | 2017-09-22 | 2020-06-17 | 이뮤노젠 아이엔씨 | 면역접합체에서 메티오닌 산화를 방지하는 방법 |
| MA54088A (fr) * | 2018-10-30 | 2022-03-16 | Immunogen Inc | Procédés de traitement faisant appel à des immunoconjugués anti-cd123 |
| WO2020092344A1 (en) * | 2018-10-31 | 2020-05-07 | Health Research, Inc. | Combination treatment with anti-cd123 antibody drug conjugate and parp inhibitor |
| KR20220004669A (ko) | 2019-04-29 | 2022-01-11 | 이뮤노젠 아이엔씨 | 항-cd123 면역접합체를 포함하는 치료적 조합물 |
-
2020
- 2020-04-29 KR KR1020217036821A patent/KR20220004669A/ko active Pending
- 2020-04-29 CN CN202080037081.6A patent/CN113853217A/zh active Pending
- 2020-04-29 US US16/862,358 patent/US11701428B2/en active Active
- 2020-04-29 WO PCT/US2020/030478 patent/WO2020223351A1/en not_active Ceased
- 2020-04-29 CA CA3137454A patent/CA3137454A1/en active Pending
- 2020-04-29 AU AU2020265225A patent/AU2020265225A1/en active Pending
- 2020-04-29 SG SG11202110702WA patent/SG11202110702WA/en unknown
- 2020-04-29 TW TW109114329A patent/TWI865521B/zh active
- 2020-04-29 EP EP20798446.9A patent/EP3962528A4/en active Pending
- 2020-04-29 JP JP2021564299A patent/JP7585231B2/ja active Active
- 2020-04-29 MA MA055816A patent/MA55816A/fr unknown
-
2021
- 2021-10-20 IL IL287446A patent/IL287446A/en unknown
-
2023
- 2023-06-02 US US18/328,288 patent/US20240033371A1/en active Pending
-
2024
- 2024-11-05 JP JP2024193438A patent/JP2025023995A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022533009A5 (enExample) | ||
| JP7822424B2 (ja) | 急性骨髄性白血病治療のための抗－ｃｄ７０抗体ａｒｇｘ－１１０の使用 | |
| DeAngelo et al. | Inotuzumab ozogamicin in adults with relapsed or refractory CD22-positive acute lymphoblastic leukemia: a phase 1/2 study | |
| JP2005533001A5 (enExample) | ||
| CN103282050A (zh) | 包含特异性识别cd38的抗体和硼替佐米的抗肿瘤组合 | |
| CN110381938A (zh) | 减少中性粒细胞缺乏症的方法 | |
| JP2022553293A5 (enExample) | ||
| CN110785184A (zh) | 用于治疗癌症的方法，组合物和试剂盒 | |
| TW202207976A (zh) | 使用免疫檢查點抑制劑抗體治療癌症之方法和組合 | |
| EP4376885A1 (en) | Methods for treating acute myeloid leukemia with anti-ilt3 antibodies | |
| JP2022513405A5 (enExample) | ||
| JP2017515843A5 (enExample) | ||
| WO2021213523A1 (zh) | 抗pd-1抗体和抗ctla-4抗体的组合在预防或治疗癌症中的用途 | |
| CN121548431A (zh) | 包含偶联物的药物组合的治疗方法和用途 | |
| WO2024026019A1 (en) | Methods for treating chronic myelomonocytic leukemia with anti-ilt3 antibodies | |
| JP7705353B2 (ja) | Ｃｄ３８抗体を使用する併用療法 | |
| CN119031933B (zh) | 蛋白酶体抑制剂与抗pd-1抗体的药物组合 | |
| US20250019441A1 (en) | Treatment of cancer with anti-ilt2 antibodies | |
| KR20200105825A (ko) | 삼중 음성 유방암의 치료를 위한 ｐｄ－１ 항체 및 아파티닙의 조합 치료의 용도 | |
| RU2021130429A (ru) | Терапевтические комбинации, содержащие иммуноконъюгаты anti-cd123 | |
| HK40112285A (en) | Use of anti cd70 antibody argx-110 to treat acute myeloid leukaemia | |
| WO2023030532A1 (zh) | 用于治疗食管癌的药物组合 | |
| WO2022007947A1 (zh) | 抗cd47抗体或其抗原结合片段和dna甲基化转移酶抑制剂的组合及其用途 | |
| EP4735037A1 (en) | Combination therapies for the treatment of non-small cell lung cancer | |
| CN121443321A (zh) | 治疗组合及其用途和治疗方法 |